Association of metabolic and genetic heterogeneity in head and neck squamous cell carcinoma with prognostic implications: integration of FDG PET and genomic analysis
- PMID: 31754877
- PMCID: PMC6872695
- DOI: 10.1186/s13550-019-0563-0
Association of metabolic and genetic heterogeneity in head and neck squamous cell carcinoma with prognostic implications: integration of FDG PET and genomic analysis
Abstract
Purpose: The linkage between the genetic and phenotypic heterogeneity of the tumor has not been thoroughly evaluated. Herein, we investigated how the genetic and metabolic heterogeneity features of the tumor are associated with each other in head and neck squamous cell carcinoma (HNSC). We further assessed the prognostic significance of those features.
Methods: The mutant-allele tumor heterogeneity (MATH) score (n = 508), a genetic heterogeneity feature, and tumor glycolysis feature (GlycoS) (n = 503) were obtained from the HNSC dataset in the cancer genome atlas (TCGA). We identified matching patients (n = 33) who underwent 18F-fluorodeoxyglucose positron emission tomography (FDG PET) from the cancer imaging archive (TCIA) and obtained the following information from the primary tumor: metabolic, metabolic-volumetric, and metabolic heterogeneity features. The association between the genetic and metabolic features and their prognostic values were assessed.
Results: Tumor metabolic heterogeneity and metabolic-volumetric features showed a mild degree of association with MATH (n = 25, ρ = 0.4~0.5, P < 0.05 for all features). The patients with higher FDG PET features and MATH died sooner. Combination of MATH and tumor metabolic heterogeneity features showed a better stratification of prognosis than MATH. Also, higher MATH and GlycoS were associated with significantly worse overall survival (n = 499, P = 0.002 and 0.0001 for MATH and GlycoS, respectively). Furthermore, both MATH and GlycoS independently predicted overall survival after adjusting for clinicopathologic features and the other (P = 0.015 and 0.006, respectively).
Conclusion: Both tumor metabolic heterogeneity and metabolic-volumetric features assessed by FDG PET showed a mild degree of association with genetic heterogeneity in HNSC. Both metabolic and genetic heterogeneity features were predictive of survival and there was an additive prognostic value when the metabolic and genetic heterogeneity features were combined. Also, MATH and GlycoS were independent prognostic factors in HNSC; they can be used for precise prognostication once validated.
Keywords: 18F-fluorodeoxyglucose; Heterogeneity; MATH; Positron emission tomography; Radiogenomics.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures







Similar articles
-
Tumor heterogeneity measured on F-18 fluorodeoxyglucose positron emission tomography/computed tomography combined with plasma Epstein-Barr Virus load predicts prognosis in patients with primary nasopharyngeal carcinoma.Laryngoscope. 2017 Jan;127(1):E22-E28. doi: 10.1002/lary.26172. Epub 2016 Jul 20. Laryngoscope. 2017. PMID: 27435352
-
Heterogeneity index evaluated by slope of linear regression on 18F-FDG PET/CT as a prognostic marker for predicting tumor recurrence in pancreatic ductal adenocarcinoma.Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):1995-2003. doi: 10.1007/s00259-017-3755-8. Epub 2017 Jun 20. Eur J Nucl Med Mol Imaging. 2017. PMID: 28634684
-
Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.Head Neck. 2017 Jun;39(6):1155-1165. doi: 10.1002/hed.24738. Epub 2017 Mar 6. Head Neck. 2017. PMID: 28263422
-
High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma.Cancer. 2013 Aug 15;119(16):3034-42. doi: 10.1002/cncr.28150. Epub 2013 May 20. Cancer. 2013. PMID: 23696076 Free PMC article.
-
Tumor Metabolic Features Identified by 18F-FDG PET Correlate with Gene Networks of Immune Cell Microenvironment in Head and Neck Cancer.J Nucl Med. 2018 Jan;59(1):31-37. doi: 10.2967/jnumed.117.194217. Epub 2017 Jun 6. J Nucl Med. 2018. PMID: 28588149
Cited by
-
KSNM60 in Clinical Nuclear Oncology.Nucl Med Mol Imaging. 2021 Oct;55(5):210-224. doi: 10.1007/s13139-021-00711-9. Epub 2021 Aug 31. Nucl Med Mol Imaging. 2021. PMID: 34721714 Free PMC article. Review.
-
A Genomic Information Management System for Maintaining Healthy Genomic States and Application of Genomic Big Data in Clinical Research.Int J Mol Sci. 2022 May 25;23(11):5963. doi: 10.3390/ijms23115963. Int J Mol Sci. 2022. PMID: 35682641 Free PMC article. Review.
-
A study on metabolic characteristics and metabolic markers of gastrointestinal tumors.Cancer Biol Ther. 2023 Dec 31;24(1):2255369. doi: 10.1080/15384047.2023.2255369. Cancer Biol Ther. 2023. PMID: 37705174 Free PMC article.
-
Insights into pet-based radiogenomics in oncology: an updated systematic review.Eur J Nucl Med Mol Imaging. 2025 Sep;52(11):4184-4199. doi: 10.1007/s00259-025-07262-7. Epub 2025 Apr 7. Eur J Nucl Med Mol Imaging. 2025. PMID: 40192792 Free PMC article.
-
Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from 68Ga-DOTATOC PET/MRI with simultaneous acquisition of apparent diffusion coefficient.BMC Cancer. 2020 Apr 16;20(1):326. doi: 10.1186/s12885-020-06836-y. BMC Cancer. 2020. PMID: 32299391 Free PMC article.
References
Grants and funding
LinkOut - more resources
Full Text Sources